=== SUMMARY ===
- The author pitches Lantheus ($LNTH) as an undervalued "cash cow" in the biotech and medical imaging sector.
- The thesis relies on the continued dominance of PYLARIFY for prostate cancer imaging and the rapid sales growth of NEURACEQ for Alzheimer's diagnosis.
- Quality assessment: Moderate DD. The post highlights strong qualitative catalysts and specific product revenue growth, but lacks the deep financial valuation metrics (P/E, FCF, etc.) typically expected in value investing.
=== SENTIMENT ===
BULLISH
=== TRADE IDEAS ===
LNTH - LONG | confidence: 0.85 | sentiment: +0.80
Speaker: u/AsAboveSoBelow322
Thesis:
1. THE FACT: FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter.
2. THE BRIDGE: The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue.
3. THE VERDICT: Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products.
4. RISKS: Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.
Timeframe: medium-term
Key Points:
- LNTH is an undervalued biotech cash cow.
- PYLARIFY is the #1 prostate cancer imaging agent.
- New PYLARIFY formulation expands market reach.
- NEURACEQ sales grew from $20M to $31M recently.
- Dementia crisis provides massive TAM for NEURACEQ.
Оценка25
Комментарии6
% апвоутов89%
▶ Полный текст поста
Lantheus is a undervalued biotech play. With their current pipeline I believe many are missing out on a easy biotech cash cow play.
Lantheus is a medical imaging company. FDA recently approved a new formulation for PYLARIFY. PYLARIFY is used for prostate cancer. The new formulation improvements are expected to increase batch sizes, to reach more patients and serve broader geographic markets. PYLARIFY is recognized as the leading PSMA PET imaging agent, with extensive use across the United States. PYLARIFY (piflufolastat F 18) is the #1 ordered PSMA PET imaging agent in the U.S. for detecting prostate cancer, utilized in over 760,000+ scans.
NEURACEQ \*\*\*is used to help diagnose Alzheimer's disease and other cognitive (mental) problems\*\*\*. Recent quarter the sales of Neuraceq was $31 million. The quarter before that sales came in around $20 million.
Lantheus sales team is very good a promoting their medical imaging agents. Pylarify is a blockbuster imaging agent. I expect neuraceq to do the same. Dementia is a rapidly growing crisis in the U.S.
FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter. The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue. Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products. Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.
This Reddit post, published March 09, 2026,
features u/AsAboveSoBelow322
discussing LNTH.
1 trade idea extracted by AI with direction and confidence scoring.